RBC Capital lowered the firm’s price target on Axsome Therapeutics to $130 from $131 and keeps an Outperform rating on the shares. Axsome reported continued growth for Auvelity and major catalysts still on track for 2H24, and the firm believes Auvelity can continue on its growth trajectory given increasing prescriber adoption, improving payer coverage, and an expanded salesforce, the analyst tells investors in a research note. RBC also seea favorable reward/risk into the ADVANCE-2 and ACCORD-2 readouts in 2H24. RBC would use the dip to buy shares given strong base business performance and potential upside from near-term phase III catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- 3 Best Stocks to Buy Now, 8/6/2024, According to Top Analysts
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- Axsome Therapeutics reports Q2 EPS ($1.67), consensus ($1.33)
- Axsome Therapeutics Inc. (AXSM) Q2 Earnings Cheat Sheet